BULK-DATA-CENTERS
30.11.2021 08:07:05 CET | Business Wire | Press release
DE-CIX , the world’s leading Internet Exchange (IX) operator and home to the largest carrier and data center neutral interconnection ecosystem globally, today announces its expansion to the Nordic region. DE-CIX has partnered with Bulk Data Centers , which will house DE-CIX IX platforms in Oslo, Norway (OS-IX), Kristiansand, Norway (Campus N01), as well as in Esbjerg, Denmark (Campus DK01). DE-CIX will also be opening IX platforms in Finland.
DE-CIX’s expansion into the Nordic region will open the Nordics to international customers, providing 100 percent green-powered Internet Exchanges through Bulk’s data centers. In addition, local Nordic customers will now get faster and more efficient access to global internet exchange services.
“The Nordic region comprises some of the world’s most highly developed digital markets,” says Ivo Ivanov, CEO of DE-CIX International, on the company’s expansion to Northern Europe. “However, the interconnection infrastructure available in the region does not match the digital maturity of the economy in the Nordics. DE-CIX has seen strong support from the Nordic data center community for our plans to expand to the region, in which we will localize our interconnection capabilities for these markets, at the same time as integrating them into the DE-CIX European and trans-continental interconnection ecosystem,” Ivanov explains.
For the market entry into the Nordics, Bulk Data Centers, a part of Bulk Infrastructure Group, will be the initial partner supporting DE-CIX from Day 1. Bulk Infrastructure is Norway’s leader in building and operating sustainable digital infrastructure, data center, colocation, fiber network and industrial real estate. The DE-CIX interconnection platforms will be available in the Bulk data centers in Oslo (OS-IX) and Kristiansand (Campus N01) (Norway), as well as Esbjerg (Campus DK01) (Denmark).
“This partnership with DE-CIX will further enhance the options for customers to interconnect and access a range of services in addition to the already low latency access to major markets combined with the greenest cheapest energy in Europe,” says Gisle M. Eckhoff, Executive Vice President Data Centers at Bulk Infrastructure. “We are seeing an increase in demand for low cost, highly sustainable solutions and with these new DE-CIX Nordics locations we are helping to support that gravity shift North. We are delighted to build on our previous investments to unlock the potential of the Nordics and look forward to working with DE-CIX to enable more customers to take advantage of renewable, long term sustainable data centers.”
The Internet Exchange operator’s expansion to Norway, Denmark and Finland will serve the regional connectivity needs, boosted by new transatlantic and intercontinental submarine cables bridging the Nordics with North America and Asia. DE-CIX will fully integrate the Nordic exchanges into the company’s existing leading carrier and data center neutral interconnection ecosystem – the largest such in not only Central and Southern Europe, consisting of more than 10 IXs (2100+ connected networks), but also North America, with currently 5 IXs (400+ connected networks).
The new DE-CIX Internet Exchanges in the Nordics will have presences in all relevant data center facilities in the respective markets.
With the new DE-CIX IX platforms in Norway, Denmark and Finland, the company is extending its global footprint to overall 32 locations in Europe, North America, the Middle East, and Asia. The combined connected customer capacity of all DE-CIX locations worldwide exceeds 85 Terabits, making it the largest neutral interconnection ecosystem in the world.
About Bulk Data Centers
Bulk Data Centers delivers resiliency, cost efficiency, scalability and sustainability without compromise and with a dedication to personalized service excellence. As a trusted advisor offering strategically located Nordic data centers, Bulk enables customers to reduce costs and environmental impact while supporting data with highly connected, 100 percent green-powered and ultra-flexible colocation, white space, build-to-suit data center solutions and powered land. Backed by decades of expertise, Bulk delivers turnkey digital infrastructure that takes the sustainability and business value of the Nordic data center to the next level.
About DE-CIX
DE-CIX (German Commercial Internet Exchange) is the world’s leading operator of Internet Exchanges. In total, in its 32 locations in Europe, North America, the Middle East, and Asia, DE-CIX interconnects over 2400 network operators (carriers), Internet service providers (ISPs), content providers, and enterprise networks from more than 100 countries, offering peering, cloud, and interconnection services. The combined connected customer capacity of all DE-CIX locations worldwide exceeds 85 Terabits, making it the largest neutral interconnection ecosystem in the world. DE-CIX in Frankfurt, Germany, with a data throughput of more than 10 Terabits per second (Tbps) and over 1000 connected networks, is one of the largest Internet Exchanges in the world.
Further information at www.de-cix.net
View source version on businesswire.com: https://www.businesswire.com/news/home/20211129005723/en/
Link:
Social Media:
https://www.facebook.com/DECIX.Internet.Exchange/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Niagen Bioscience Receives Exclusive U.S. FDA Rare Pediatric Disease (RPD) Designation and European Medicines Agency Orphan Medicinal Product Designation (OMPD) for NB4168 for the Treatment of Ataxia Telangiectasia (A-T)13.7.2026 14:32:00 CEST | Press release
Regulatory recognition in the United States and Europe supports the development of NB4168, a novel small molecule candidate for a rare pediatric disease with no approved treatments Niagen Bioscience, Inc. (NASDAQ: NAGE), the global authority on NAD+ (nicotinamide adenine dinucleotide) with a focus on the science of healthy aging, today announced that the U.S. Food & Drug Administration (FDA) granted Rare Pediatric Disease (RPD) Designation for its proprietary lead small molecule drug candidate NB4168 for the treatment of Ataxia Telangiectasia (A-T). NB4168 is an oral small molecule therapy engineered to deliver substantially greater nicotinamide riboside (NR) exposure than conventional NR while maintaining a differentiated pharmacokinetic and safety profile. In addition, the European Medicines Agency (EMA) has granted Orphan Medicinal Product Designation (OMPD) to NB4168 for the treatment of A-T, providing regulatory recognition in the European Union and further supporting the Company'
SLB OneSubsea Awarded EPC Contract for Eni’s Baleine Phase 3 Project Offshore Côte d'Ivoire13.7.2026 14:00:00 CEST | Press release
Integrated subsea production system and local capabilities enable accelerated deepwater development Global energy technology company SLB (NYSE: SLB) announced today that its OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260712734539/en/ SLB OneSubsea™ joint venture has been awarded a major multi-well engineering, procurement, and construction (EPC) contract by Eni for Phase 3 of the deepwater Baleine project offshore Côte d’Ivoire. Under the contract, SLB OneSubsea will deliver complete subsea production systems (SPS) for 13 wells, reinforcing its role as a core technology and execution partner on one of the most strategically significant offshore developments currently underway in the region. The EPC scope includes subsea trees, um
HistoSonics Receives CE Mark, Unlocking Access Across Europe and Accelerating Global Commercialization of the Edison® Histotripsy Platform13.7.2026 14:00:00 CEST | Press release
HistoSonics, today announced that the company has received CE Mark approval in Europe for its Edison® System, enabling commercialization of the company’s non-invasive histotripsy technology in Europe and other markets that recognize the CE Mark. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260713505048/en/ HistoSonics Edison® Histotripsy System The Edison System is a novel, non-invasive, image guided platform that is intended for the destruction of liver tumors, including the partial or complete destruction of unresectable liver tumors. It uses the mechanical properties of focused ultrasound, called histotripsy, to liquefy and destroy unwanted tissue and tumors in a single procedure without the need for invasive procedures or radiation, and with potentially fewer side effects than traditional therapies. CE Mark approval follows an increasing number of regulatory clearances and was supported by a growing body of clinical ev
Esri Introduces ArcGIS Velocity for ArcGIS Enterprise to Power Real-Time GIS Operations13.7.2026 14:00:00 CEST | Press release
ArcGIS Velocity Brings Real-Time Data Ingestion, Analysis, and Automated Alerting to ArcGIS Enterprise Deployments Esri announces that ArcGIS Velocity is now available for ArcGIS Enterprise, enabling real-time data analytics and automated actions in self-hosted environments. This capability’s new deployment unifies real-time workflows across ArcGIS Online and ArcGIS Enterprise. This update benefits organizations across industries: public safety, transportation, logistics, and more. Esri, the global leader in location intelligence, has released for general availability ArcGIS Velocity for ArcGIS Enterprise for self-hosted deployments on Windows and Linux. This enables organizations to leverage Velocity from secure on-premises and private cloud environments. Available as software as a service (SaaS) for ArcGIS Online and now for self-hosted environments in ArcGIS Enterprise, Esri’s next-generation geospatial capability delivers real-time analytics on streaming, Internet of Things (IoT),
Agenus Announces Oversubscribed Private Placement of Up to $340 Million to Advance Registrational ROBBIN Trial of Neoadjuvant BOT+BAL in MSS Colon Cancer13.7.2026 12:00:00 CEST | Press release
$85M upfront financing, along with up to $255 million upon exercise of purchase warrants, is expected to fund ROBBIN1, Agenus' registrational Phase 3 trial of neoadjuvant botensilimab and balstilimab (BOT+BAL) in microsatellite-stable (MSS) colon cancer Transaction is structured to fund Agenus through key value-inflection points, including interim topline pathologic response data and interim and final event-free survival (EFS) analyses, with proceeds to fund Agenus operations through year-end 2031, assuming full warrant exercise ROBBIN target population in MSS colon cancer represents a >$7 billion addressable annual sales opportunity in the US for which no new therapies have been approved in over 20 years2,3 To focus resources on the neoadjuvant opportunity, Agenus is discontinuing financial support for the ongoing BATTMAN Phase 3 study in late-line metastatic MSS colorectal cancer Company to host conference call and webcast today at 8:30 a.m. ET Agenus Inc. (Nasdaq: AGEN), a leader in
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
